Deep Medicine Acquisition Corp. Rights
DMAQR
DMAQR was delisted on the 31st of January, 2024.
30 hedge funds and large institutions have $388K invested in Deep Medicine Acquisition Corp. Rights in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.
3% less funds holding
Funds holding: 31 → 30 (-1)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
65% less capital invested
Capital invested by funds: $1.1M → $388K (-$713K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$49.3K |
| 2 |
CS
Clear Street
New York
|
+$41.7K |
| 3 |
PL
Parkwood LLC
Cleveland,
Ohio
|
+$14.6K |
| 4 |
Walleye Capital
New York
|
+$11.1K |
| 5 |
BRF
B. Riley Financial
Los Angeles,
California
|
+$3.33K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
HGC Investment Management
Toronto,
Ontario, Canada
|
-$88K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$20.4K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.96K |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$2.21K |
| 5 |
MC
Meteora Capital
Boca Raton,
Florida
|
-$371 |
DMAQR Hedge Fund Activity: Q3 2022 in Review
30 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Deep Medicine Acquisition Corp. Rights (DMAQR) for Q3 2022, worth a combined $388K — down 65% from $1.1M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of DMAQR and 2 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 4 added.
The largest buyer was Cowen and Company, adding an estimated $49.3K. The largest seller was HGC Investment Management, exiting entirely with an estimated $88K sold.
- 30 institutional investors held Deep Medicine Acquisition Corp. Rights (DMAQR) as of Q3 2022, down from 31 in Q2 2022.
- Funds reported $388K of Deep Medicine Acquisition Corp. Rights stock for Q3 2022, down 65% quarter-over-quarter.
- 2 funds opened new Deep Medicine Acquisition Corp. Rights positions in Q3 2022 and 3 closed out, a net change of -1 holder.
- The largest Deep Medicine Acquisition Corp. Rights buyer in Q3 2022 was Cowen and Company, an estimated $49.3K added.
- The largest Deep Medicine Acquisition Corp. Rights seller in Q3 2022 was HGC Investment Management, an estimated $88K sold.
Based on aggregated 13F filings for Q3 2022.